Trial · NCT00052078
Child and Adolescent Anxiety Disorders (CAMS)
NCT00052078, Phase 3, Completed, Johns Hopkins University; results first posted 2017-04-25
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Child and Adolescent Anxiety Disorders (CAMS). Trials, record NCT00052078. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00052078
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Child and Adolescent Anxiety Disorders (CAMS)
- NCT number
- NCT00052078
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 488 participants, actual
- Lead sponsor
- Johns Hopkins University
- Conditions
- Anxiety Disorders, Social Phobia, Generalized Anxiety Disorder
- Interventions
- Sertraline (SRT), Cognitive Behavioral Therapy (CBT), Placebo
- First posted
- 2003-01-23
- Last updated
- 2017-09-19
- Results first posted
- 2017-04-25
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Clinical Global Impression - Improvement Scale | Measured at Week 12 | The Clinical Global Impression - Improvement scale (CGI-I) is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention and rated as: 1-Very much improved; 2-Much improved; 3-Minimally improved; 4-No change; 5-Minimally worse; 6-Much worse; 7-Very much worse. Response rates are reported as a percentage of participants who score 1-Very much improved; 2-Much improved on the The Clinical Global Impression - Improvement scale. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Clinical Global Impression - Improvement Scale | Measured at Week 12 | percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Clinical Global Impression - Improvement Scale | 1 Setraline | 54.9 | 95% Confidence Interval 46.4 to 63.1 | percentage of participants | |
| Clinical Global Impression - Improvement Scale | 2 CBT | 59.7 | 95% Confidence Interval 51.4 to 67.5 | percentage of participants | |
| Clinical Global Impression - Improvement Scale | 3 Combination Setraline and CBT | 80.7 | 95% Confidence Interval 73.3 to 86.4 | percentage of participants | |
| Clinical Global Impression - Improvement Scale | 4 Placebo | 23.7 | 95% Confidence Interval 15.5 to 34.5 | percentage of participants |
Source ClinicalTrials.gov
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | 1 Setraline | 133 | |
| Overall Study | STARTED | 2 CBT | 139 | |
| Overall Study | STARTED | 3 Combination Setraline and CBT | 140 | |
| Overall Study | STARTED | 4 Placebo | 76 | |
| Overall Study | COMPLETED | 1 Setraline | 110 | |
| Overall Study | COMPLETED | 2 CBT | 133 | |
| Overall Study | COMPLETED | 3 Combination Setraline and CBT | 127 | |
| Overall Study | COMPLETED | 4 Placebo | 61 | |
| Overall Study | NOT COMPLETED | 1 Setraline | 23 | |
| Overall Study | NOT COMPLETED | 2 CBT | 6 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events12
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Worsening of Behavior | Psychiatric disorders | 1 Setraline | 1 | 133 | 1 |
| serious | Worsening of Behavior | Psychiatric disorders | 2 CBT | 0 | 139 | 0 |
| serious | Worsening of Behavior | Psychiatric disorders | 3 Combination Setraline + CBT | 0 | 140 | 0 |
| serious | Worsening of Behavior | Psychiatric disorders | 4 Placebo | 0 | 76 | 0 |
| serious | Oppositional-Defiant Behavior | Psychiatric disorders | 1 Setraline | 0 | 133 | 0 |
| serious | Oppositional-Defiant Behavior | Psychiatric disorders | 2 CBT | 0 | 139 | 0 |
| serious | Oppositional-Defiant Behavior | Psychiatric disorders | 3 Combination Setraline + CBT | 1 | 140 | 1 |
| serious | Oppositional-Defiant Behavior | Psychiatric disorders | 4 Placebo | 0 | 76 | 0 |
| serious | Tonsillectomy | Surgical and medical procedures | 1 Setraline | 1 | 133 | 1 |
| serious | Tonsillectomy | Surgical and medical procedures | 2 CBT | 0 | 139 | 0 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse eventsAdverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | 1 Setraline | ||
| Total, all-cause mortality | 2 CBT | ||
| Total, all-cause mortality | 3 Combination Setraline + CBT | ||
| Total, all-cause mortality | 4 Placebo | ||
| Total, other adverse events | 1 Setraline | 0 | 133 |
| Total, other adverse events | 2 CBT | 0 | 139 |
| Total, other adverse events | 3 Combination Setraline + CBT | 0 | 140 |
| Total, other adverse events | 4 Placebo | 0 | 76 |
| Total, serious adverse events | 1 Setraline | 2 | 133 |
| Total, serious adverse events | 2 CBT | 0 | 139 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers20
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U01MH064089 | Child/Adolescent Anxiety Multimodal Treatment Study | GINSBURG, GOLDA SUSAN | JOHNS HOPKINS UNIVERSITY | NATIONAL INSTITUTE OF MENTAL HEALTH | 2002 to 2007 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00052078
GET https://conductscience.org/api/trials/v1/NCT00052078/registered